The global bone growth stimulator market size was estimated at USD 1.0 billion in 2016. Increasing prevalence of arthritis globally is a major factor contributing to the growth of the market. Rising prevalence of arthritis due to aging and obesity are leading factors contributing to the growth of the market. Aging individuals are the most susceptible to osteoarthritis and gouty arthritis. As stated by Arthritis Foundation, over 50 million Americans were suffering from arthritis in 2016, and this number is expected to reach78.4 million by 2040. Thus, the widespread occurrence of arthritis is driving demand for these products.
A growing number of trauma and accident cases is considered as one of the high impact rendering drivers likely to boost demand for the products. According to the CDC, annually, around 41 million people in the U.S visit the emergency department with traumatic injuries. Road accidents and trauma are likely to result in several severe spinal injuries as well as delayed union & nonunion fractures, which require surgical treatment. These devices promote healing of bones during treatment of failed spinal fusions, delayed unions, fracture nonunion, and fresh fractures by applying an ultrasonic or electrical current to the fusion site.
Bone Morphogenetic Proteins (BMP) and Platelet-rich Plasma (PRP) products assist in bone growth during the treatment of various fractures and spinal surgeries. Thus, the adoption of these products is anticipated to increase during these surgeries due to faster healing resulting in quick recovery. Hence, with the rising number of accidents and trauma cases, the number of spinal and orthopedic surgeries is increasing. This rise has further accelerated demand for these devices, BMP, and PRP products, which is projected to drive market growth.
Frequent product recalls have been observed to hamper the overall growth of the market. Recall of products has an adverse effect on a manufacturer’s business and reputation. This could also affect the loyalty of the customers to other products of a company. In addition, recalls also question the efficiency of new products, and thereby, delay their adoption by surgeons. For instance, in May 2017, Zimmer Biomet’s SpF XL IIb and SpF PLUS-Mini implantable spinal stimulators were recalled and the FDA classified it as a Class I recall. This recall was initiated owing to potentially harmful chemicals that could lead to serious adverse effects, including paralysis, chronic infections, and death.
In 2016, the external devices segment accounted for the largest share of the market owing to an increase in demand for noninvasive surgical treatments for bone healing. In addition, these devices are usually lightweight, battery-powered, portable, and easy to handle, as a result, they are being increasingly adopted by patients.
In addition, the availability of advanced products, such as CMF OL1000 Bone Growth Stimulators and CMF SpinaLogic Bone Growth Stimulators, is expected to boost market development. Moreover, external stimulator devices are less expensive as compared to invasive internal devices, which is projected to increase their adoption in developing countries such as South Africa, India, and China.
The BMP and PRP segment is expected to exhibit lucrative growth over the forecast period owing to the rising incidence of arthritis, spinal injuries, and trauma & accident cases. According to the CDC, annually, around 54.4 million adults in the U.S. had some form of rheumatoid arthritis, arthritis, lupus, gout, or fibromyalgia from 2013 to 2015. In addition, PRP has high safety, lower adverse effects, and no risk of an allergic reaction, and these factors are expected to boost the growth of the segment.
There are several leading vendors, including Medtronic; Stryker; DePuy Synthes Companies; Arthrex, Inc.; Bioventus LLC; and TERUMO BCT, INC. that provide advanced devices for treatment of spinal fusion, delayed fracture union, nonunion bone fractures, etc.
The spinal fusion surgeries segment dominated the market in terms of revenue in 2016. Increased incidence of spinal cord injuries such as fractures, spinal stenosis, and herniated disc injuries has led to increased demand for spinal fusion surgeries across the globe. According to WHO, worldwide, around 250,000 to 500,000 people suffer from spinal cord injuries annually, mainly because of road accidents, falls, and violence.
Moreover, increasing incidence of age-related spinal problems and fractures are driving the market. Aging leads to lowering of bone density and weakening of bones due to excessive loss of bone mass, and this is likely to result in fractures & spinal problems. According to the U.S. Census Bureau, around 617.1 million people were aged 65 years and older in 2015, and this number is expected to reach about 1,000.0 million by 2030. A surge in the geriatric population prone to osteoarthritis conditions is primarily driving demand for these products globally.
The delayed union and nonunion bone fracture segment is expected to grow at a significant rate during the study period. There is a high prevalence of osteoporosis that causes pain and debilitating fractures, which is expected to propel market growth. According to the International Osteoporosis Foundation, osteoporosis causes about 8.9 million fractures annually. In addition, around 1.6 million hip fractures take place globally each year, and this number is projected to reach between 4.5 and 6.3 million by 2050.
Manufacturers are focusing on the launch of new and advanced products to cater to the unmet needs of healthcare professionals and patients. For instance, in January 2017, Orthofix International N.V. announced the approval of CervicalStim and SpinalStim, bone growth stimulators used for postoperative spinal fusion, by U.S. FDA and European Commission (CE Mark). These devices deploy a low-level pulsed electromagnetic field that activates and enhances the natural healing process of the body.
Hospitals and clinics held the largest market share owing to increasing admission of patients suffering from traumatic injuries, road accidents, spinal injuries, and fractures. Thus, this segment dominated the market in 2016 owing to high patient turnaround and frequent readmissions for surgery and other treatments.
Furthermore, increasing focus on the development of healthcare infrastructure in developing countries of Asia Pacific and African regions is expected to propel the growth of the segment. Rising disposable income and the availability of advanced medical devices for the treatment of different chronic diseases are expected to boost the usage of these products in hospitals and clinics.
The homecare segment is expected to showcase lucrative growth during the forecast period due to product advancements and rising healthcare awareness among people. These devices are lightweight & portable and can be easily handled by patients at home for management of arthritis, fractures, acute & chronic pain, and osteoporosis. Thus, the availability of advanced noninvasive products is projected to drive the adoption of these home-use products.
The other end-use segment consists of research institutes and ambulatory surgical centers. This segment is projected to witness lucrative CAGR during the forecast period owing to a substantial rise in the number of spine fusion surgeries performed in ambulatory surgical centers. In addition, research institutes are actively involved in the study of BMP and PRP to improve and increase their clinical applications, which is anticipated to propel growth.
North America dominated the bone growth stimulator market with the largest revenue share owing to the high prevalence of osteoporosis or vertebral fractures. According to the American Association of Neurological Surgeons, in the U.S., 8 million women are suffering from osteoporosis and 25% of women are estimated to be affected by Vertebral Compression Fractures (VCFs). An increase in the prevalence of osteoporosis and VCFs has led to a rise in demand for bone growth stimulators used for enhanced healing, which boosts the market growth.
Europe was the second-largest market for bone growth stimulators due to the high demand for innovative therapies for chronic diseases and the local presence of leading medical device manufacturers such as Medtronic; Orthofix Holdings, Inc.; Zimmer Biomet; Bioventus; Stryker; and Terumo BCT, Inc. In addition, highly developed healthcare infrastructure primarily in Germany, Switzerland, the UK, and France is expected to drive the regional market.
Asia Pacific region is expected to exhibit the highest CAGR during the study period due to the growing number of road accidents and trauma cases. According to World Road Statistics, around 5,00,279 road accidents occurred in 2015 in India as compared to 4,93,474 in 2014, representing a 1.4% increase in the number of injuries. Thus, a large number of road accidents in India boost the demand for these products.
The market is fragmented, with the presence of a large number of local and global players. Several big companies operating in the industry are Orthofix Holdings, Inc.; Medtronic; Zimmer Biomet; DJO Global, Inc; Bioventus LLC; Stryker; DePuy Synthes; Arthrex, Inc.; Isto Biologics; and Terumo BCT, Inc. Major manufacturers provide advanced products through strong distribution channels across the globe. For instance, Medtronic has a presence in around 260 locations globally in more than 150 countries.
Leading players are involved in strategic collaborations, mergers & acquisitions, and new product development to gain revenue share in the industry. Strategic collaborations and mergers & acquisitions help companies expand their existing business and geographical reach. For instance, in May 2016, Zimmer Biomet completed the acquisition of Cayenne Medical, Inc. —a leading developer of advanced soft tissue repair as well as reconstruction solutions for shoulders, knees, and extremities.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, India, China, Brazil, Mexico, South Africa, Saudi Arabia
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global bone growth stimulators market on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million; 2014- 2025)
Bone growth stimulation devices
External bone growth stimulators
Combined Magnetic Field (CMF) devices
Capacitive Coupling (CC) devices
Pulsed Electromagnetic Field (PEMF) devices
Implanted bone growth stimulators
Ultrasonic bone growth stimulators
Bone Morphogenetic Proteins (BMP)
Platelet-Rich Plasma (PRP)
Application Outlook (Revenue, USD Million; 2014 - 2025)
Spinal fusion surgeries
Delayed union & nonunion bone fractures
Oral and maxillofacial surgeries
End-use Outlook (Revenue, USD Million; 2014 - 2025)
Hospitals and clinics
Regional Outlook (Revenue, USD Million; 2014 - 2025)
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.